Elevidys delandistrogene moxeparvovec-xxxx injection for intravenous use


T CEA TA EN G ID

Please see Important Safety Information on page 4 and accompanying full Prescribing Information.

Introduction to ELEVIDYS

ELEVIDYS is a prescription gene therapy used to treat individuals with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the dystrophin gene and are ambulatory. It is not a cure.

ELEVIDYS is a single-dose intravenous infusion – readministration is not recommended. There are several essential steps required both before and after infusion day, including ongoing monitoring.



This guide is not intended to replace the advice of your child's doctor. Please follow the advice and guidance of your child's doctor.

What is ELEVIDYS?

ELEVIDYS is a prescription gene therapy used to treat ambulatory individuals with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the dystrophin gene. ELEVIDYS was approved under accelerated approval. Accelerated approval allows for drugs to be approved based on a marker that is considered reasonably likely to predict a clinical benefit. ELEVIDYS treatment increased the marker, ELEVIDYS dystrophin, in skeletal muscle in patients. Verification of a clinical benefit may be needed for ELEVIDYS to continue to be approved. Individuals with certain type of mutations, any deletion that includes exons 9-13 in the DMD gene should not receive ELEVIDYS.


Please see additional <u>Important Safety Information</u> on page 4 and accompanying full <u>Prescribing Information</u>.

delandistrogene moxeparvovec-xxxx injection for intravenous use

REMINDERS

Treatment with ELEVIDYS

There are 5 main steps to treatment with ELEVIDYS



1-888-SAREPTA (1-888-727-3782) Monday through Friday, 8:30am – 6:30pm ET

> Elevidys delandistrogene moxeparvovec-xxxx injection for intravenous use

Please see additional <u>Important Safety Information</u> on page 4 and accompanying full <u>Prescribing Information</u>.

3

WHO IS ELIGIBLE?

PREPARATION I

REMINDERS

Important Safety Information



What is ELEVIDYS (delandistrogene moxeparvovec-xxxx)?

ELEVIDYS is a prescription gene therapy used to treat ambulatory individuals with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the dystrophin gene. ELEVIDYS was approved under accelerated approval. Accelerated approval allows for drugs to be approved based on a marker that is considered reasonably likely to predict a clinical benefit. ELEVIDYS treatment increased the mar' VIDYS dystrophin, in skeletal muscle in patients. Verification of a clinical ' nay be needed for ELEVIDYS to continue to be approved.



Who should not receive ELEVIDYS?

Individuals with certain type of mutations, any deleter the ordes exons in the DMD gene should not receive ELE

)	What is the m	OSt :	rtant infc	atic	know (It ELEVIDYS?
/	ELEVIDYS	.ease	enzyme	rela	,é dc	serious liver injury.
	Detients wi	eive c	ul cortico	oid be	fore and afte	er infusion with ELEVIDYS and
	rgo?		rts to	itor liv	ver function.	Contact the patient's doctor
	imme əly it	patier	nt	or white	s of the eyes	appear yellowish, or if the
	patien ses	t se of	corticostero	id or voi	mits it up.	

Administic ion of LLEVIDYS may be delayed in patients who have acute liver disease un+" condition is resolved or under control. Patients with pre-existing liver curment or chronic liver infection may be at higher risk of acute serious liver injury.

A life-threatening reaction involving a type of muscle damage called immunemediated myositis happened in a clinical study patient one month after receiving the ELEVIDYS infusion. Caregivers should contact the patient's doctor immediately if the patient experiences symptoms including severe muscle weakness, difficulty swallowing, breathing, or speaking due to weakened vocal cords.

The patient's doctor will conduct blood tests to determine platelet counts, as well as a blood test to evaluate a cardiac protein called troponin-I which can detect damage to muscle cells in the heart. Increased troponin-I has been seen following ELEVIDYS infusion, including a serious case.

> Elevidys delandistrogene moxeparvovec-xxxx injection for intravenous use

Please see accompanying full Prescribing Information.

AFTER TREATMENT

Important Safety Information (continued)



What is the most important information to know about ELEVIDYS? (continued)

Patients need to have blood tests to ensure that they do not have antibodies that may prevent them from being able to receive ELEVIDYS as introducing the gene therapy could increase the risk of a severe allergic reaction. Treatment with ELEVIDYS is not recommended for patients who have high antibodies to the vector, part of gene therapy used to deliver ELEVIDYS.

Due to the need to follow a corticosteroid regimen before and c LL YS, caregivers should be aware that signs of an infection bor after influence or after influence or after influence coughing, wheezing, sneezing, runny nose, sore to participate or after could lead on the serious complications. Caregivers should contact patient' loctor immediately if they see any symptoms suggestive faction.



Are there any considerations fo			ICL	ions sci	iles and ELEVIDYS?
Patient's var		ld be u	date	urrer	nunization guidelines.
Vaccinatic	nould be	eived a		ee, r	to starting the corticosteroid
imen thu	equi	efore rec	ng ELE	VIDYS.	

Are to any caution. need to be considered when handling patient's bodily ste?

Vector Jding C ELEVIDYS occurs primarily through body waste. Patients and care should use good hand hygiene when coming into direct contact with patient , waste. Precautions should be followed for one month after receiving ELEVIDYS.



What are the possible or likely side effects of ELEVIDYS?

The most common side effects that occurred in patients treated with ELEVIDYS were vomiting and nausea.

Other reported side effects included increased liver function tests, fever, and decreased platelet counts.

The safety information provided here is not comprehensive. Talk to the patient's doctor about any side effects that bother the patient or that don't go away.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782).

Elevidys delandistrogene moxeparvovec-xxxx injection for intravenous use

Please see accompanying full Prescribing Information.

AFTER TREATMENT

5

Who is eligible for ELEVIDYS

Before treatment with ELEVIDYS, your doctor will need to take the following steps to check that your child is eligible:



Ambulatory

Your child's doctor will confirm that your child is ambulatory.



Genetic test

Your doctor will review your child's genetic test to c m a mutation in the DMD gene in order to be eligible for to trent.

Ъ.

ELEVIDYS cannot be used in peopl exons 9 to 13 in the Trene. deletion t fully includes



ີ່ງody t

You, tor w arrorn. I tes measure the presence of antibodies to the ELEVIL rector Vrh74). Yo aroctor will use a specific test provided by Sarepta.

Individe may nearally develop antibodies to the vector (AAVrh74) in ELEVIDYS. This reasons that the immune system would recognize the vector, potentially causing lous immune response after the ELEVIDYS infusion. If your child's immune system nas anti-AAVrh74 antibodies above the required threshold, your child may not be eligible for ELEVIDYS.



Enrollment Form

You and your child's doctor must complete and submit an ELEVIDYS Enrollment Form.



Please see additional <u>Important Safety Information</u> on page 4 and accompanying full <u>Prescribing Information</u>.

6

Preparing for treatment

The following will need to be completed in advance of your child's infusion day:



Vaccination

If possible, your child's immunizations should be up-to-date with current immunization guidelines prior to starting the corticosteroid regimen required before F' ation of the corticosteroid regimen.



Weight check

Your doctor will confirm your child's to help de

che right dose of JIDYS.

(

Preinfusion

Your docto perform od test a clinica — am before the infusion day. These vill eve nction, plc t count, and troponin-I levels. Your doctor will r child's infusion as part of safety monitoring. If fter repu ese atory e liver disc , your doctor may postpone ELEVIDYS administration your c has until it i olve controlled.



Jorticosteroid regimen

To help reduce the risk of an immune response to ELEVIDYS, your doctor will prescribe an ELEVIDYS treatment-related corticosteroid regimen prior to receiving ELEVIDYS. Your child will need to continue to take this course of corticosteroids for at least 2 months (60 days) after infusion, as recommended by your doctor. This regimen is in addition to any other oral corticosteroid treatment that your child may currently be taking.

YOUR CHILD:	WHEN TO START ELEVIDYS TREATMENT-RELATED CORTICOSTEROID REGIMEN:
 Currently takes corticosteroids 	1 day before infusion day
× Does not currently take corticosteroids	1 week before infusion day

Always follow your doctor's instructions about your child's ELEVIDYS treatment-related corticosteroid regimen, and talk to your doctor if you have any questions or concerns.

Please see additional <u>Important Safety Information</u> on page 4 and accompanying full <u>Prescribing Information</u>.

Elevidys delandistrogene moxeparvovec-xxxx injection for intravenous use

7

AFTER TREATMENT

Infusion day

ELEVIDYS is given as a single-dose intravenous infusion



Administration

A small tube inserted by a needle will deliver the therapy into a vein in your child's arm.



Duration

The actual infusion will last approximately 1 to 2 hours, but you treatment visit may be as long as a full day, based a doctor's clinical jud

IMPORTANT NOT

Tell your docto cany signs or simpling a control bef inDYS administion. In your child has sign fection reinfusion i i e postponed, du th preased risk of a serious imune response



Please see additional <u>Important Safety Information</u> on page 4 and accompanying full <u>Prescribing Information</u>.

8

After treatment



Postinfusion corticosteroid regimen

Immune responses to the AAVrh74 vector can occur after administration of ELEVIDYS. To reduce the risk of an immune response, continue with the ELEVIDYS-related corticosteroid regimen prescribed by your doctor.

Your child should take this course of corticosteroids for at least 60 days. Your octor will tell you when to adjust, taper and/or stop this treatment-related cor* Jid regimen.

Note: If your child's blood test results or clinical exams show yet anctic onormalities following ELEVIDYS infusion, your doctor may increase unild's cortice oid dose temporarily.

Contact your doctor if your classes a cor	oid dose or von	
Due to corticostoroid use, in tion cold, flu str	ointestinal issues, ear	
infection 'n, etc) k re or infusio u	Ild lead to more serious	
com dons. Cal ur doct and ou see o	any symptoms that are	
sugges of infe (eg, cou g, sneezing, runny no	se, sore throat, or fever).	
Postil on n toring		
Your ch vill ne veekly monitoring tests for		
3 mont our doctor will monitor the following:		
, and the second s	See pages 11-12	
. function through blood tests and clinical	for ELEVIDYS	
exams (weekly for 3 months)	treatment	

Blood test results (for 1 month); your doctor will monitor your child's platelet counts (weekly for the first 2 weeks) and troponin-I levels to monitor for cardiac muscle damage (weekly for 1 month)

treatment reminders

Follow your doctor's instructions for ongoing monitoring. Your doctor may continue monitoring for longer periods of time.



Hand hygiene

Small amounts of ELEVIDYS may be found in your child's body waste (urine, feces, saliva), so proper hand hygiene is important for 1 month after ELEVIDYS infusion.

Hand washing is one of the most effective ways to prevent the spread of germs. Clean hands can stop germs from spreading from one person to another. Follow these steps each time you come into contact with body fluids and waste.


Please see additional Important Safety Information on page 4 and accompanying full Prescribing Information.

Elevidys delandistrogene moxeparvovec-xxxx injection for intravenous use

After treatment (continued)

Safety considerations for ELEVIDYS

Side effects can happen, so it's important to know what to look out for.



Your child's immune system may recognize the vector in ELEVIDYS, potentially causing a serious immune response.

Elevidys delandistrogene moxeparvovec-xxxx injection for intravenous use

Please see additional <u>Important Safety Information</u> on page 4 and accompanying full <u>Prescribing Information</u>.

ELEVIDYS treatment reminders

Important reminders after ELEVIDYS infusion

You may find it helpful to print this page and review with your doctor before you leave the treatment center.



ELEVIDYS can increase liver enzyme levels and cause acute serious liver injury. It also can cause a serious immune response in the muscles, call annunemediated myositis.



Contact your doctor immediately if:

- Your child's skin and/or whites of the eyes appendic this may be a sign of increased the symes
- Your child experiences any une tendernese s, incluc difficul allowing, athing, vocal co as this , be a sig nusci nune-r

, y	mes					
in	reased	cle pain,				
seve	∽cle w	ness,				
		∧ _akened				
a severe immune reaction in						
iated	l myositis					

Call 911 with any lifethreatening concerns

Use property in the provided of the second s

he most common side effects are nausea and vomiting.

Other side effects include low platelet count and fever, in addition to increased liver enzymes and immune-mediated myositis. Report any side effects to your doctor.

Use this space for notes from speaking with your doctor about postinfusion monitoring.

Elevidys delandistrogene moxeparvovec-xxxx injection for intravenous use

Please see additional <u>Important Safety Information</u> on page 4 and accompanying full Prescribing Information.

ELEVIDYS treatment reminders (continued)

After ELEVIDYS infusion, your child will have a specific posttreatment corticosteroid regimen and monitoring plan

You may find it helpful to print this page and use it as a reminder during the posttreatment monitoring period.



Corticosteroid regimen

It's important to follow your doctor's instructions for treatment of costeroid use to help reduce the risk of an immune response to a risk. Your child take this course of corticosteroids for at least 60 days reinfusion.

MY CHILD'S DAILY POST-ELEVIDYS CORTI

- Call your doctor if your child mis
- Due to cortione, infectlung in., etc) bee or afteCall youctor immately if ycoug.runny ne

a or vomin up (eg, c ⁿu, gas intestinal issues, ear infection, f¹ in ad infore serious complications. Le any synctoms that are suggestive of infection sore throat, or fever)



Monity 3 sci yle

Your do will n for your child through blood tests to monitor liver function (weekly for first for first for first onths), platelet counts (weekly for first 2 weeks), and troponin-I (weekly for first for first 2 weeks), and troponin-I (weekly for first for first 2 weeks), and troponin-I (weekly for first 2 weeks), and troponi

Use the chart below to write in the date and help track your weekly appointments.

	WEEK 1	WEEK 2	WEEK 3	WEEK 4	WEEK 5
MONTH 1					
MONTH 2					
MONTH 3					

For questions along the way, contact your doctor.

In case of emergency, call 911.

Please see additional <u>Important Safety Information</u> on page 4 and accompanying full <u>Prescribing Information</u>.



© 2023 Sarepta Therapeutics, Inc. 215 First Street, Cambridge, MA 02142. All rights reserved. 5/23 C-GT01-US-0033 SAREPTA, SAREPTA THERAPEUTICS, the SAREPTA Helix logo, SAREPTASSIST, and the SAREPTASSIST Logo are registered trademarks of Sarepta Therapeutics, Inc. registered in the U.S. Patent and Trademark Office and may be registered in various other jurisdictions. ELEVIDYS and the ELEVIDYS logo are trademarks of Sarepta Therapeutics, Inc.

Elevidys delandistrogene moxeparvovec-xxxx injection for intravenous use